SCHEMBL1364768

SCHEMBL1364768

C[Si](C)(C)C(O)C(O)[Si](C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11040415 0.73
SCHEMBL2309 0.70
SCHEMBL3128037 0.70
SCHEMBL7058997 0.67
SCHEMBL17960005 0.67
SCHEMBL7935312 0.61 ALDH1A1 (0.36) ALDH1A1LMNA
SCHEMBL1645069 0.60 ALDH1A1 (0.33) ALDH1A1
SCHEMBL1107768 0.56
SCHEMBL14488948 0.56
SCHEMBL231828 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50634-E1 Diaryl macrocycles as modulators of protein kinases Turning Point Therapeutics, Inc. (US) 2025-10-14 US disclosed
US-12404281-B2 Diaryl macrocycles as modulators of protein kinases Turning Point Therapeutics, Inc. (US) 2025-09-02 US disclosed
US-20240140964-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. (US) 2024-05-02 US disclosed
EP-4338739-A2 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. (US) 2024-03-20 EP disclosed
EP-3636649-B1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TURNING POINT THERAPEUTICS INC (US) 2024-02-14 EP disclosed
CN-110317214-B Diaryl macrocycles as modulators of protein kinases 特普医药公司 2022-11-22 CN disclosed
CN-110317213-B Diaryl macrocycles as modulators of protein kinases 特普医药公司 2022-10-18 CN disclosed
EP-3572416-B1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES TURNING POINT THERAPEUTICS INC (US) 2022-09-21 EP disclosed
US-20220112213-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES Turning Point Therapeutics, Inc. 2022-04-14 US disclosed
US-8569521-B2 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors MERCK SHARP & DOHME CORP. (US) 2013-10-29 US disclosed
EP-1976843-B1 CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME (US) 2013-09-04 EP disclosed
US-20120264736-A1 BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS SCHERING CORPORATION (US) 2012-10-18 US disclosed
US-8067621-B2 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors SCHERING CORPORATION (US) 2011-11-29 US disclosed
US-20070197581-A1 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors MERCK SHARP & DOHME LLC 2007-08-23 US disclosed
US-20060121069-A1 Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins DUKE UNIVERSITY (US) 2006-06-08 US disclosed
EP-1066254-B1 C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS FP AGONISTS UNIV DUKE (US) 2005-05-25 EP disclosed
EP-1082299-B1 C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS MEDICAMENTS UNIV DUKE (US) 2004-06-30 EP disclosed
US-20020146439-A1 Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins DUKE UNIVERSITY 2002-10-10 US disclosed
US-6444840-B1 BONE DISORDERS; VISION DEFECTS THE PROCTER & GAMBLE CO. 2002-09-03 US disclosed
US-6410780-B1 BONE DISORDERS; VISION DEFECTS THE PROCTER & GAMBLE CO. 2002-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112213-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES MAP3K20, LCK, MAP3K1 ALDH1A1 4630/4885LMNA 4097/4885
US-12404281-B2 Diaryl macrocycles as modulators of protein kinases MAP3K20, LCK, MAP3K1 ALDH1A1 4630/4885LMNA 4097/4885
US-20240140964-A1 DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES MAP3K20, LCK, MAP3K1 ALDH1A1 4630/4885LMNA 4097/4885
US-20020146439-A1 Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins PTGES, PTGS2, PTGS1 ALDH1A1 843/4885LMNA 806/4885
US-20120264736-A1 BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS BACE1, PSEN1, BACE2 ALDH1A1 2826/4885LMNA 2290/4885
US-20070197581-A1 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors BACE1, BACE2, PSEN1 ALDH1A1 2806/4885LMNA 2368/4885
US-20060121069-A1 Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins PTGES, PTGS2, PTGS1 ALDH1A1 843/4885LMNA 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.